U.S. FDA faces mounting criticism over Alzheimer's drug approval

Cynthia Flagg (R) sits with her husband Charles, who took part in an early stage trial of Biogen's drug aducanumab following his diagnosis with Alzheimer's disease. On June 7, 2021 the U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) as the first treatment to target a likely underlying cause of Alzheimer's disease - sticky deposits of a protein called amyloid beta. Picture taken February 21, 2020. (REUTERS/Brian Snyder)





Your feedback is important to us!

We invite all our readers to share with us their views and comments about this article.

Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.

Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (

comments powered by Disqus



Interested in knowing more about this story?

Click here